was then possible to develop software for calculating the dose distribution at any angle made of the applicator with the surface. Results: The software calculates the dose distribution by varying the angle and the depth to which you want to know. The variation of homogeneity is very important. For an angle of 25°, the inhomogeneity in the surface plane is between 100 and 40 %. Conclusions: A software has been developed, based on the computation code PENELOPE to know the dose distribution at any depth as a function of angle applicator with the surface. Purpose/Objective: IORT is becoming an increasingly popular approach for cancer treatment. Especially patients with very close or positive margins after resection or recurrent cancer benefit from IORT. For situations where a flat area (up to 6cm in diameter) has to be treated intraoperatively, new applicators for superficial treatment with a miniature x-ray source (INTRABEAM ® System, Carl Zeiss Surgical GmbH, Oberkochen, Germany) were developed. They were evaluated using ionization chamber and film dosimetry. Materials and Methods: Each of the so called FLAT (1 -6cm diameter) and SURFACE Applicators (1cm -4cm diameter) consists of a radiation protective metal tube and a flattening filter, which converts the spherical dose distribution of the x-ray source into a flat one. The homogeneity of each dose distribution and depth dose measurements were evaluated using film dosimetry (Gafchromic EBT2 films, ISP, New Jersey, USA) in a solid water phantom (Gammex 457, Gammex Inc., Middleton, WI, USA) and a soft x-ray ionization chamber (Type 34013, PTW, Freiburg, Germany) in a water tank (Carl Zeiss Surgical GmbH, Oberkochen, Germany).
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Purpose/Objective: A new method for in vivo dosimetry (IVD) during breast intraoperative radiation therapy (IORT) was carried out to improve informations on the dose actually delivered to the target and on the alignment of the shielding disk. With this method it is possible to acquire two bi-dimensional dose distributions: one just below the target and the other beyond the shielding disk. Materials and Methods: Breast IORT requires the protection of the tissues underneath the target volume. This is achieved by the surgeon positioning a shielding disk between the residual breast and the pectoralis fascia. The position of the disk is a very suitable location for performing IVD. In our experience we prepared two layers of radiochromic films, Gafchromic ® EBT3 of the same size of the shielding disk, we fixed them by sterile tape to both sides of the disk, which was then delivered to the surgeon for subsequent placement. The gafchromic films were calibrated in dose for the two energy (6 and 9 MeV) usually employed in breast cancer treatment to provide a bi-dimensional distribution in term of absolute dose. After each treatment the radiochromic films were read by a CCD scanner producing two digital images suitable for subsequent analysis. Results: The Department of Radiotherapy of Trieste has recently implemented a IORT dedicated electron-beam accelerator, the Intraop ® Mobetron. The first patients were treated immediately after conservative surgery for breast carcinoma, and two in vivo dose maps were acquired for all of them. The image related to the film positioned on top of the disk allowed us to evaluate the mean absolute dose in a central area of the exposed field to compare with the prescribed dose. In all cases we obtained excellent agreement. The uniformity of the exposed area was also evaluated (Fig.1 ).
Fig.1 -Images of the EBT3 Gafchromic
® film located on the upper face of the shielding disk. a) Original image (green channel); b) Representation enhancing the dishomogeneities of the target. From the image related to the lower film position we were able to measure the dose that actually crosses the shielding. We employed new shielding disks provided by IntraOp ® company, made by stacking a 5 mm perspex layer, a 3 mm copper layer and 2 mm perspex layer. With these disks we always measured negligible transmission values. Geometrical analysis of the position of the exposed area can provide information about the extent of the unavoidable misalignment between the treatment field and the protective disk. In this way it is possible to evaluate the amount of dose that escapes from the shielding and that provides undesirable dose to healthy tissues. Conclusions: High dose IORT treatment requires high accuracy. For this reason IVD represents a very important test to evaluate the actual delivered dose. Gafchromic ® EBT3 film prooves an effective and appropriate dosimeter to be surgically applied to the patient. The absolute dose measurement provides verification of the correct exposure to the target, as well as an estimation of the dose to the healthy tissue. high local/systemic relapse risk were selected. We enrolled patients with ≤ 70 years age, without clinical nodal disease, and at least two of following characteristics: pre-operative PSA >10 ng/ml and <20ng/ml; Gleason score ≥7; cT2c; or at least one of following characteristics: apical gland involved; pre-operative PSA >20ng/ml and <50ng/ml; Gleason score ≥8; cT≥3. Before the surgery the Ethical Board validated informed consent for adjuvant IORT was obtained. The surgery included radical prostatectomy with iliac-obturator lymphadenectomy and extemporaneous histological examination for nodal metastasis research. After prostate removal the patients were irradiated with IORT receiving a radical dose of 20 Gy in single fraction by 10 MeV electron beam. The IORT procedure was performed after bladderurethral anastomosis and confirmation of pathological negativity of 2nd ESTRO Forum 2013 S379 obturator nodes. In vivo dosimetry was performed by mosfet dosimeters inserted in rectal and Foley catheters. The toxicity was evaluated according to RTOG scale. Results: Of the 8 patients selected, 1 was excluded from IORT for nodal metastasis found during the extemporaneous histological examination and performed adjuvant external beam radiotherapy afterwards; 7 patients were treated with IORT 20 Gy after radical prostatectomy. One patient died several months after IORT for noncancer related causes. In 6/8 patients the pathological staging confirmed the clinical staging with the evidence of an high risk of relapse after surgery (see table) . In 2 (pT2c pN0 Mo R0) patients prognostic factors for local relapse had overestimate the stage. No patients had acute toxicity. The average time of hospitalization was 6 days (range 5-8). The median follow-up was 28 months (range 26-36). In 6/7 (86%) patients so far alive we didn't observe biochemical relapse (average PSA <0,008 ng/ml). No patient performed hormonal therapy. No early urinary or rectal toxicity ≥G1 was observed. 2/6 (33%) patients reported late urinary stenosis easily resolved after dilatation. No patients had urinary incontinence. 
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